– USA, NC – TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the appointment of William N. Kelley, M.D. to serve on its Board of Directors. The appointment will be effective January 1, 2015, and increases the size of the TransEnterix Board of Directors to nine members. The Board of Directors determined that Dr. Kelley is an independent director.
“I am excited to be joining the TransEnterix Board of Directors,” commented Dr. Kelley. “TransEnterix’ patient-side SurgiBot system can address a significant unmet need in surgical robotics, and I am impressed by TransEnterix’ strong culture of innovation.”
Dr. Kelley has over 40 years of health care experience including health care system management, education and research, and currently serves as Professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. His past experience includes serving as Executive Vice President of the University of Pennsylvaniawith responsibilities as Chief Executive Officer for the Medical Center, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. Dr. Kelley has also served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Dr. Kelley currently serves on the Board of Directors of GenVec, Inc., and previously served on the Board of Directors of Merck & Co. Inc., Beckman Coulter, Inc., Advanced Biosurfaces, Inc. and Polymedix, Inc. Dr. Kelley has served on the editorial boards of 13 medical journals, and his bibliography includes more than 300 publications and 17 books. Dr. Kelley received his medical degree from Emory University.
With this appointment, the TransEnterix Board of Directors will consist of Paul LaViolette, TransEnterix’ Chairman of the Board, Todd M. Pope, TransEnterix’ President and CEO, Dennis Dougherty, Managing General Partner of Intersouth Partners, Jane H. Hsiao, Ph.D., Vice-Chairman and Chief Technical Officer of OPKO Health, Inc., Aftab R. Kherani, M.D., Partner of Aisling Capital, David Milne, Managing Partner of SV Life Science Advisors, Richard C. Pfenniger, Jr., former Chairman, CEO and President of Continucare Corporation, William Starling, Managing Director, Synergy Life Science Partners and Dr. Kelley.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery. The company is focused on the development and commercialization of the SurgiBot™ system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
